Pioglitazone Treatment Enlarges Subcutaneous Adipocytes in Insulin-Resistant Patients
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
CONTEXT: Obesity-related insulin resistance is associated with an increase in adipocyte size. In rodent models, treatment with the insulin-sensitizers thiazolidinediones (TZDs) leads to the appearance of small, insulin-sensitive adipocytes. Whether such TZD-dependent morphological changes occur in adipose tissue of insulin-resistant patients is unclear. OBJECTIVE: The objective of the study was to study the effects of treatment with the TZD pioglitazone on sc adipose tissue morphology and function in insulin-resistant subjects. DESIGN: This was a placebo-controlled, randomized crossover study. SETTING: The study was conducted at a university medical center. PATIENTS: Twelve adult patients with congenital adrenal hyperplasia (CAH) characterized by insulin resistance were included in this study. INTERVENTION: After a 4-wk run-in phase, patients were treated with pioglitazone (45 mg/d) followed by placebo, each for 16 wk or vice versa. MAIN OUTCOME MEASURES: After both placebo and pioglitazone treatment, insulin sensitivity was determined by hyperinsulinemic euglycemic clamp and abdominal sc adipose tissue was obtained to measure adipocyte cell surface and expression of genes involved in glucose uptake and inflammation. RESULTS: Pioglitazone treatment significantly improved the insulin sensitivity index (placebo: 0.35 +/- 0.16 micromol/kg . min per milliunit per liter; pioglitazone 0.53 +/- 0.16 micromol/kg . min per milliunit per liter, P < 0.001) and increased mRNA expression levels of adiponectin and glucose transporter-4 in adipose tissue. The increase in insulin sensitivity was accompanied by a significant enlargement of the sc adipocyte cell surface (placebo: 2323 +/- 725 microm(2); pioglitazone 2821 +/- 885 microm(2), P = 0.03). CONCLUSIONS: In the human situation, treatment of insulin-resistant subjects with pioglitazone improves insulin sensitivity, whereas at the same time, sc adipocyte cell surface increases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Relationship between Adipocyte Size and Adipokine Expression and Secretion
Skurk, T., Alberti-Huber, C., Herder, C., & Hauner, H. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1055 · Cited by 1,288 · cited 7×
“Importantly, positive correlations between adipocyte surface and plasma leptin, percentage trunk fat, and MCP-1 gene expression levels, markers indicative of insulin resistance and adipose tissue dysfunctioning, disappeared after pioglitazone-induced enlargement of adipocytes.”
BackgroundInfluentialWeyer, C., Foley, J. E., Bogardus, C., Tataranni, P. A., & Pratley, R. E. (2000) · Diabetologia · doi:10.1007/s001250051560 · Cited by 799 · cited 1×
“The positive association between obesity-induced adipocyte hypertrophy and the development of insulin resistance and T2DM has been reported before (4).”
BackgroundLarson-Meyer, D. E., Heilbronn, L. K., Redman, L. M., Newcomer, B. R., Frisard, M. I., Anton, S., Smith, S. R., Alfonso, A., Ravussin, E., & the Pennington CALERIE Team (2006) · Diabetes Care · doi:10.2337/dc05-2565 · Cited by 504
Failure of adipocyte differentiation causes type II diabetes mellitus?
Danforth, E. (2000) · Nature Genetics · doi:10.1038/79111 · Cited by 487 · cited 1×
“The development of hypertrophic adipocytes is partly explained by the impaired ability to differentiate new fat cells, resulting in enlargement of existing adipocytes (15).”
BackgroundEffect of troglitazone on body fat distribution in type 2 diabetic patients.
Mori, Y., Murakawa, Y., Okada, K., Horikoshi, H., Yokoyama, J., Tajima, N., & Ikeda, Y. (1999) · Diabetes Care · doi:10.2337/diacare.22.6.908 · Cited by 281
Charmandari, E., Weise, M., Bornstein, S. R., Eisenhofer, G., Keil, M. F., Chrousos, G. P., & Merke, D. P. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.5.8456 · Cited by 164 · cited 2×
“These patients are characterized by insulin resistance (12) and were used in this study as a human model for obesity-associated insulin resistance.”
BackgroundMethod
Cited by
Glucagon-like peptide 1 regulates adipogenesis in 3T3-L1 preadipocytes
YANG, J., REN, J., SONG, J., LIU, F., WU, C., WANG, X., GONG, L., LI, W., XIAO, F., YAN, F., et al. (2013) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2013.1350 · Cited by 84
Du, Q., Wang, Y.-J., Yang, S., Wu, B., Han, P., & Zhao, Y.-Y. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.681636 · Cited by 53
Du, Q., Yang, S., Wang, Y.-J., Wu, B., Zhao, Y.-Y., & Fan, B. (2012) · Advances in Therapy · doi:10.1007/s12325-012-0044-6 · Cited by 47
Metadata
- Authors
- Koenen, T. B., Tack, C. J., Kroese, J. M., Hermus, A. R., Sweep, F. C. G., van der Laak, J., Stalenhoef, A. F. H., de Graaf, J., van Tits, L. J. H., & Stienstra, R.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2009-11-01
- Volume
- 94
- Issue
- 11
- Pages
- 4453-4457
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2022288751
- Cited by
- 40
- References
- 6
- FWCI
- 2.47
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pioglitazone Treatment Enlarges Subcutaneous Adipocytes in Insulin-Resistant Patients. https://app.cochat.ai/papers/10.1210/jc.2009-0517
- The paper
- Koenen, T. B., Tack, C. J., Kroese, J. M., Hermus, A. R., Sweep, F. C. G., van der Laak, J., Stalenhoef, A. F. H., de Graaf, J., van Tits, L. J. H., & Stienstra, R. (2009). Pioglitazone Treatment Enlarges Subcutaneous Adipocytes in Insulin-Resistant Patients. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2009-0517
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.